Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis to Prevent Cytomegalovirus Disease in Lung Transplant Recipients (CYTOCOR STUDY): An Open-label, Randomised, Non-inferiority Clinical Trial.
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Ganciclovir (Primary) ; Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Acronyms CYTOCOR
- 11 Nov 2019 Status changed from not yet recruiting to recruiting.
- 08 Mar 2019 Planned End Date changed from 1 Jun 2023 to 1 Jul 2023.
- 08 Mar 2019 Planned primary completion date changed from 1 Mar 2023 to 1 Apr 2023.